港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组_老虎社区_美港股上老虎

港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组

智通财经04-22

智通财经APP获悉，宜明昂科-B(01541)涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72(ActRIIA-Fc融合蛋白)项目，针对肺动脉高压(PAH)适应症的健康人群的多次给药剂量递增(MAD)研究，已顺利完成全部受试者入组。这一进展标志着IMC-003项目...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2629097539?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-22 14:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629097539","market":"hk","top_or_hot":-1,"title":"港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72(ActRIIA-Fc融合蛋白)项目，针对肺动脉高压(PAH)适应症的健康人群的多次给药剂量递增(MAD)研究，已顺利完成全部受试者入组。这一进展标志着IMC-003项目...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1431820.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 宜明昂科-B(01541)涨超5% 子公司宜明凯尔已完成IMC-003项目MAD研究全部受试者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-22 14:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1431820.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，宜明昂科-B(01541)涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72(ActRIIA-Fc融合蛋白)项目，针对肺动脉高压(PAH)适应症的健康人群的多次给药剂量递增(MAD)研究，已顺利完成全部受试者入组。这一进展标志着IMC-003项目...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1431820.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1431820.html","article_id":"2629097539","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629097539","pubTimestamp":1776840465,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，宜明昂科-B涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72项目，针对肺动脉高压适应症的健康人群的多次给药剂量递增研究，已顺利完成全部受试者入组。据介绍，与现有同类药物相比，IMC-003具有独特的差异化特性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","01541":"宜明昂科-B","BK4588":"碎股","BK1161":"生物科技"},"translate_title":"Changes in Hong Kong stocks | Yiming Angke-B (01541) rose by more than 5%. Subsidiary Yiming Kaier has completed the enrollment of all subjects in the MAD study of IMC-003 project","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"01541":1.5},"content_text":"智通财经APP获悉，宜明昂科-B(01541)涨超5%，截至发稿，涨5.29%，报5.77港元，成交额898.42万港元。消息面上，4月22日，据宜明昂科-B官微消息，公司宣布，其子公司宜明凯尔自主研发的IMC-003/IMM72(ActRIIA-Fc融合蛋白)项目，针对肺动脉高压(PAH)适应症的健康人群的多次给药剂量递增(MAD)研究，已顺利完成全部受试者入组。这一进展标志着IMC-003项目的临床开发进程迈出坚实一步，为评估其在多次给药下的安全性、耐受性、药代动力学及药效学特征奠定了重要基础。据介绍，与现有同类药物相比，IMC-003具有独特的差异化特性。其ActRIIA受体胞外段功能区经过基因工程改造，能够增强与配体Activin A的结合和阻断活性，同时提高药物的质量均一性。在Sugen5416-低氧和MCT诱导的肺动脉高压动物模型中，IMC-003展现出优异的药效且优于现有同类药物。IMC-003对Activin A的高选择性使其在临床应用中有望在更低暴露下取得良好疗效，并可能降低出血风险，展现更好的安全性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}